<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="102329">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01669460</url>
  </required_header>
  <id_info>
    <org_study_id>12-5041-C</org_study_id>
    <nct_id>NCT01669460</nct_id>
  </id_info>
  <brief_title>Study of Red Bull™ Sugar-Free Drink for Reduction of Fatigue in Prostate Cancer Patients Receiving LHRH Agonist Therapy</brief_title>
  <official_title>A Phase II, Open Label Study of Red Bull™ Sugar-Free Drink for Reduction of Fatigue in Prostate Cancer Patients Receiving LHRH Agonist Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <authority>Canada: University Health Network Research Ethics Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to find out if Red Bull™ Sugar-Free Drink can reduce
      fatigue in prostate cancer patients receiving LHRH agonist therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Reduction in overall fatigue as measured by Bruera global fatigue severity scale.</measure>
    <time_frame>Within 4 days after completion of intervention (28 days of Red Bull™)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall improvement in quality of life as measured by the Medical Outcomes Study Short-Form (SF-36)</measure>
    <time_frame>Within 4 days after completion of intervention (28 days of Red Bull™)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Fatigue</condition>
  <arm_group>
    <arm_group_label>Red Bull™ Sugar-Free Drink</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Red Bull™ Sugar-Free Drink: two (250mL) cans per day for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Red Bull™ Sugar-Free Drink</intervention_name>
    <description>Red Bull™ Sugar-Free Drink two (250mL) cans per day for 28 days</description>
    <arm_group_label>Red Bull™ Sugar-Free Drink</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed prostate cancer

          -  Currently receiving LHRH-agonist therapy for greater than 6 months

          -  Measurable fatigue, defined as a score of ≥ 2 on the Bruera global fatigue severity
             scale

          -  Able to swallow Red Bull™ Sugar-Free Drink

          -  Life expectancy of at least 1 year

          -  Able to read and write in English

          -  Willing to limit consumption of alcohol to one drink per day

        Exclusion Criteria:

          -  Current malignancy or received treatment for a previous malignancy within the last 3
             years other than prostate cancer (exceptions are superficial bladder cancer or
             non-melanoma skin cancer)

          -  Myocardial infarction within past 6 months

          -  Any unstable serious co-existing medical condition(s) including but not limited to
             unstable or poorly controlled coronary artery disease, chronic atrial fibrillation,
             uncontrolled hypertension, uncontrolled diabetes, severe bleeding diseases or immune
             disorders

          -  Evidence of drug or alcohol abuse

          -  Known hypersensitivity to caffeine

          -  Known history of liver and kidney insufficiencies

          -  Known contraindications to Red Bull™ use
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil Fleshner, MD, FRCSC, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 1C1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 18, 2013</lastchanged_date>
  <firstreceived_date>August 16, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fatigue</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
